Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 1, 2017




(Exact Name of Registrant as Specified in Charter)




Delaware   001-35945   26-1349956

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

400 Technology Square, Cambridge,


(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 229-5872


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 2.02 Results of Operations and Financial Condition.

On November 1, 2017, Epizyme, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ended September 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information provided under Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 1, 2017, the Company announced that Peter T.C. Ho, M.D., Ph.D., the Company’s Executive Vice President and Chief Medical Officer, will be leaving the Company, effective December 31, 2017.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


99.1    Press release issued by the Company on November 1, 2017*


* The information in this exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 1, 2017     By:  

/s/ Robert B. Bazemore


Robert B. Bazemore

President and Chief Executive Officer


Exhibit 99.1




Epizyme Reports Third Quarter 2017 Operating Results and Company Updates

Company Scheduled for First FDA Interaction for Tazemetostat in NHL in 4Q17

Chief Medical Officer, Dr. Peter Ho, to Transition from Epizyme at the End of 2017; Will

Continue to Support Upcoming Clinical and Regulatory Milestones through Transition

Recent Financing Extends Operating Runway into at Least 3Q19

Conference Call to be Held Today at 4:30 p.m. ET

CAMBRIDGE, Mass., Nov. 1, 2017 — Epizyme, Inc. (NASDAQ: EPZM) today reported operating results for the third quarter 2017, recent progress in its clinical development programs for tazemetostat in non-Hodgkin’s lymphoma (NHL) and solid tumors, and company updates.

“2017 has been a year of tremendous progress, with additional important milestones remaining this quarter, including our scheduled interaction with the FDA to begin discussing the registration strategy for tazemetostat in NHL,” said Robert Bazemore, president and chief executive officer of Epizyme. “Our experienced management team is executing well on the drivers for both short and long-term Epizyme growth. Our clinical organization is delivering on a comprehensive tazemetostat clinical program according to our plans; our research team has named G9a as the target for the next program in our pipeline; and our business operations team completed a capital raise that meaningfully extended our runway. I am confident in our ability to build on this momentum as we begin the transition into a commercial company, with our first NDA submission targeted for 2018 and the potential launch of tazemetostat to follow.”

Due to the company’s transition, Peter T.C. Ho, M.D., Ph.D., chief medical officer, has decided to leave the company at the end of 2017. Throughout the rest of this year, Dr. Ho will continue to oversee all clinical programs, upcoming clinical milestones and preparation of medical congress presentations, as well as support the scheduled interaction with the U.S. Food and Drug Administration (FDA) in the fourth quarter. Epizyme is conducting an active search for a seasoned clinical executive and is in the process of securing an interim CMO to serve in a consultative capacity during the transition.

Bazemore added, “Based on our planned transformation in 2018 and his passion for early-stage drug development, Peter will be transitioning from Epizyme at the end of the year. Since joining in 2014, Peter has been instrumental in building our clinical team and bringing the tazemetostat program to where it is today. We are very thankful to Peter for his many contributions and wish him all the best in the future. This transition allows us the opportunity to add new strength to the team with a seasoned clinical executive with extensive late-stage drug development experience and a track record of driving new treatments to approval.”



Tazemetostat NHL Program Updates


    Epizyme is on-track to hold the first of multiple interactions with the FDA in the fourth quarter of 2017 to discuss its NHL program, and plans to provide an update in early 2018.


    The ongoing Phase 2 study in patients with follicular lymphoma and diffuse large B-cell lymphoma continues to enroll patients with EZH2 mutations. As a result of Epizyme’s efforts to accelerate enrollment of these patients, which includes the recently initiated collaboration with US Oncology, August and September were the highest screening months to date for the study.

Tazemetostat Solid Tumor Program Updates


    Phase 2 Mesothelioma Study: Epizyme’s ongoing Phase 2 study designed to evaluate tazemetostat as a treatment for adults with mesothelioma characterized by BAP1 loss-of-function has surpassed the futility assessment and achieved the primary endpoint of at least a 30 percent disease control rate at 12 weeks. The company expects to report data from this study in 2018. In addition, the FDA has granted Orphan Drug designation to tazemetostat for the treatment of patients with mesothelioma.


    Pediatric Phase 1 INI1-Negative Tumor Study: Data from the completed dose-escalation portion of Epizyme’s Phase 1 study of tazemetostat in pediatric patients with INI1-negative solid tumors were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Objective responses were observed in patients with epithelioid sarcoma (n=1), poorly differentiated chordoma (n=2) and atypical teratoid rhabdoid tumors (n=1) at dose levels ranging from 520 to 900 mg/m2 twice daily. Enrollment in the dose-expansion portion of the study is ongoing.


    Adult Phase 2 INI1-Negative Tumor Study: The malignant rhabdoid tumor cohort and other INI1-negative tumor cohort of the company’s ongoing Phase 2 study in molecularly defined solid tumors have both surpassed their futility assessment with objective responses observed in both populations. Epizyme is continuing to enroll and monitor patients in these arms, and plans to present updated data from this study in 2018. The company has also added a separate cohort to enroll adults with chordoma, due to the high rate of enrollment of these patients in the other INI1-negative cohort and the observed clinical activity with tazemetostat in this tumor type in both adults and children so far.

Upcoming Data Presentations


    Previously announced data on adult and pediatric epithelioid sarcoma patients in the company’s ongoing INI1-negative solid tumor studies will be presented during a plenary session at the Connective Tissue Oncology Society (CTOS) Annual Meeting at 1:00 p.m. HAST on Thursday, Nov. 9, 2017. The adult data were originally presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting and the pediatric data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.


    Epizyme will introduce the next development program in its pipeline, which addresses G9a, a novel target for the potential treatment of sickle cell disease (SCD), during a plenary presentation at the 2017 American Society of Hematology (ASH) Annual Meeting at 7:30 a.m. ET on Monday, Dec. 11, 2017. This is the first of three internally discovered programs expected to enter the clinic by the end of 2020.



    New patient data from the company’s 62-gene panel biomarker study of tazemetostat in patients with NHL will also be presented in a poster session at the ASH Annual Meeting.

Third Quarter 2017 Financial Results


    Cash Position: Cash, cash equivalents and marketable securities were $307.2 million as of September 30, 2017, as compared to $263.3 million as of September 30, 2016. The increase is mainly driven by the $151.3 million in net proceeds following the company’s underwritten public offering of 10,557,000 shares of common stock.


    Revenue: There was no revenue recognized in the third quarter of 2017, compared to $6.6 million for the third quarter of 2016, as there were no collaboration milestones during the quarter.


    R&D Expenses: Research and development (R&D) expenses were $28.7 million for the third quarter of 2017, compared to $23.9 million for the third quarter of 2016. The increase is primarily due to increased tazemetostat manufacturing activities, tazemetostat clinical development and research activities related to advancing the company’s next development program.


    G&A Expenses: General and administrative (G&A) expenses were $9.3 million for the third quarter of 2017, compared to $7.5 million for the third quarter of 2016. The increase is primarily due to increased personnel-related expenses to support the company’s growth and pre-commercial activities.


    Net Loss: Net loss was $37.6 million for the quarter ended September 30, 2017, compared to $24.3 million for the quarter ended September 30, 2016.

Financial Guidance

Epizyme provides financial guidance that the company believes that its existing cash, cash equivalents and marketable securities as of September 30, 2017 will be sufficient to fund its planned operations into at least the third quarter of 2019.

About the Tazemetostat Clinical Trial Program

Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied as a monotherapy in ongoing Phase 2 programs in both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) forms of non-Hodgkin lymphoma (NHL); certain molecularly defined solid tumors, including epithelioid sarcoma and other INI1-negative tumors; mesothelioma; and combination studies in DLBCL. Tazemetostat has been granted Fast Track designation by the U.S. Food and Drug Administration for FL regardless of EZH2 mutation status and for DLBCL with EZH2-activating mutations, as well as Orphan Drug designation for mesothelioma, soft tissue sarcoma and malignant rhabdoid tumors.

About Orphan Drug Designation

The FDA Orphan Drug designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.



About Epizyme, Inc.

Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. Using the Company’s proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme’s science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Epizyme, Inc. and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation of future clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; whether results from clinical studies will warrant meetings with regulatory authorities, submissions for regulatory approval or review by governmental authorities under the accelerated approval process; whether fast track and orphan drug designations will provide the benefits for which tazemetostat is eligible; expectations for regulatory approvals to conduct trials or to market products; whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the SEC and in the Company’s other filings from time to time with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.






Cheya Pope, Epizyme, Inc.


(617) 229-7561


Monique Allaire, THRUST


(617) 895-9511





(Amounts in thousands)


     September 30,
     December 31,

Consolidated Balance Sheets Data :


Cash, cash equivalents and marketable securities

   $ 307,228      $ 242,192  

Total assets

     320,546        252,441  

Deferred revenue

     28,809        28,809  

Total stockholders’ equity

     268,189        201,700  



(Amounts in thousands except per share data)


     Three Months Ended
September 30,
    Nine Months Ended
September 30,
     2017     2016     2017     2016  

Collaboration revenue

   $ —       $ 6,584     $ 10,000     $ 7,529  

Operating expenses:


Research and development

     28,741       23,888       80,728       63,078  

General and administrative

     9,311       7,522       28,750       20,792  













Total operating expenses

     38,052       31,410       109,478       83,870  

Loss from operations

     (38,052     (24,826     (99,478     (76,341













Other income, net

     455       490       1,335       1,145  













Net loss

   $ (37,597   $ (24,336   $ (98,143   $ (75,196













Loss per share allocable to common stockholders:



   $ (0.63   $ (0.42   $ (1.67   $ (1.32


   $ (0.63   $ (0.42   $ (1.67   $ (1.32

Weighted average shares outstanding:



     59,899       57,970       58,837       56,828  


     59,899       57,970       58,837       56,828